NCT00370682已完成2 期
Phase II, Randomized, Double-blind, Single Center, Controlled Study of Two Doses of Different Formulations of the WRAIR Live Attenuated Tetravalent Dengue Vaccine Compared to a Placebo Control, Administered on a 0-6 Month Schedule, to Healthy Adults
U.S. Army Medical Research and Development Command1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2007年4月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- Neutralizing Antibody Geometric Mean Titer (GMT) to DEN Types 1, 2, 3 and 4; 30 and 90 Days After Dose 2
研究概览
简要总结
This descriptive study will evaluate the safety and immunogenicity of different formulations of the WRAIR dengue vaccine compared to a placebo.
详细描述
Subjects will be randomized into one of three groups. One group will receive a placebo vaccine and the other two will receive different dengue vaccine formations. Each subject will receive two doses six months apart. All subjects will have 11 venipunctures during 11 visits (i.e., screening plus 10 study visits) over a period of nine months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 20 Years 至 25 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •A healthy male or female adult 20-25 years of age (≥20 years of age and ≤25 years of age) at the time of vaccination;
- •Free of obvious health problems as established by medical history and physical examination before entering into the study;
- •Written informed consent obtained from the subject;
- •Able to read the Subject Information Sheet and Consent Form;
- •Subjects who the investigator believes can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits) should be enrolled in the study;
- •females must be of non-childbearing potential, i.e. surgically sterilized or, if of childbearing potential, she must be abstinent or on adequate contraceptive precautions (i.e. intrauterine contraceptive device; oral contraceptives or other equivalent hormonal contraception, e.g. progestin implantable, cutaneous hormonal patch or injectable contraceptives) for 30 days prior to vaccination, have a negative pregnancy test within 48 hours prior to vaccination and must agree to continue such precautions for 60 days after completion of the vaccination series
排除标准
- •Pregnant or lactating female, planning to become pregnant or planning to discontinue abstinence or contraceptive precautions;
- •History of any neurological or behavioral disorder or seizures, with the exception of a single febrile seizure in childhood;
- •History of drug abuse or alcohol consumption (more than 2 drinks per day);
- •History of allergic disease/reaction likely to be exacerbated by any component of the vaccine;
- •Acute or chronic, pulmonary, cardiovascular, hepatic, renal, hematologic or endocrine functional defect, as determined by physical examination or laboratory tests;
- •Any confirmed or suspected immunosuppressive or immunodeficient condition or seropositive for HBsAg, anti-HCV or anti-HIV;
- •Acute disease at the time of enrollment (acute disease is defined as the presence of a moderate or severe illness with or without fever);
- •Chronic hepatomegaly, right upper quadrant abdominal pain or tenderness;
- •Chronic splenomegaly, left upper quadrant abdominal pain or tenderness;
- •Hypertension; chest pain, palpitations, dizziness, shortness of breath, arrhythmias or friction rubs;
- •Use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceding the study vaccine (includes placebo) or planned use during the study period;
- •Planned administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before the first dose of the study vaccine/placebo and ending 30 days after the second dose;
- •A planned move to a location that will prohibit participating in the trial for 9 months after the initial vaccination;
- •Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within 90 days preceding the first dose or planned administration during the study period. For corticosteroids, this will mean prednisone, or equivalent, 0.5 mg/kg/day. Inhaled and topical steroids are allowed;
- •Administration of immunoglobulins and/or blood products within 90 days preceding the first dose or planned administration during the study period;
- •Any chronic systemic drug therapy to be continued during the study period (except for vitamin/mineral supplements or routine treatment for gastro-esophageal reflux);
- •No easy access to a fixed or mobile telephone
结局指标
主要结局
Neutralizing Antibody Geometric Mean Titer (GMT) to DEN Types 1, 2, 3 and 4; 30 and 90 Days After Dose 2
时间窗: 30 and 90 days after dose 2
Neutralizing antibody geometric mean titer (GMT) to DEN types 1, 2, 3 and 4 will be measured 30 and 90 days following the administration of the 2nd dose (6 month)
Incidence of Any Grade 3 Solicited Adverse Events (AEs) Within 21 Days Follow-up After Dose 1
时间窗: 0-21 days after dose 1
Percentage of subjects with any grade 3 adverse events (AEs) within 21 days follow-up after dose 1 (0 month)
次要结局
- Percentage of Subjects With Neutralizing Antibodies to Each DEN Type, After Each Dose of Study Vaccines(post dose 1 and 2)
- Incidence of Measurable Dengue Viremia at Specified Time Points After Each Dose(within 7 months)
- Incidence of Unsolicited AEs Within 31 Days (Days 0-30) After Any Study Vaccine Dose(0-30 days after each study vaccine dose)
- Incidence of Serious Adverse Events (SAEs) Throughout the Entire Study Period(9 months)
- Laboratory Values Above the Alert Values Within 31 Days (Days 0-30) After Each Vaccine Dose(within 31 days after each vaccine dose)
- Subjects With Any Adverse Events (AEs) Within 21 Days Follow-up After Dose 2 of Study Vaccine(0-21 days after dose 2 of study vaccine)
- Neutralizing Antibody Sero-response to Each DEN Type (Increase Neut.) Antibody From pre-to Post-vaccination, to be Determined by a Qualified Assay) After Each Dose of Study Vaccines(9 months)
- Incidence of Abnormal Findings at DEN Physical Examination After Each Vaccine Dose(31 days post-vaccination per dose)
- Incidence of Suspected and Confirmed Dengue Throughout the Entire Study Period.(9 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US AdultsDengueNCT00350337U.S. Army Medical Research and Development Command86
已完成
2 期
RSV F Dose-Ranging Study in WomenRespiratory Syncytial Virus InfectionsNCT01960686Novavax720
终止
2 期
Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)Ulcerative ColitisNCT00307827Abbott38
已完成
2 期
A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan AdultsShigella Sonnei InfectionNCT02676895GlaxoSmithKline74
已完成
1 期
A Study on the Reactogenicity, Safety and Immune Response of a Targeted Immunotherapy Against HSV in Healthy Japanese Participants Aged 18-40 YearsHerpes SimplexNCT05989672GlaxoSmithKline50